| Cancer Research UK Invests 10m Pounds In Drug Discovery
Cancer Research UK is investing 10m pounds in drug discovery projects at four universities across the UK.
Project leaders at Imperial College London, University of Oxford, University of Strathclyde and The School of Pharmacy in London will each receive £500k per year for five years to develop anti-cancer drugs.
The grants aim to encourage research into using small molecules to create new and targeted drugs to treat cancer. The projects will range from developing therapies for leukaemia to discovering new drugs to beat drug resistance in breast and prostate cancer treatments.
Professor Herbie Newell, Cancer Research UK's executive director of clinical and translational research, said: "We are in the process of significantly expanding our drug discovery programmes.
Family counseling improves lives of patients and spouses coping with ...
Families coping with prostate cancer report improved quality of life from a structured support program integrated into the patients cancer management, according to a new study. The findings appear in the December 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society. This randomized clinical trial by Dr. Laurel Northouse from the University of Michigan and co-investigators found that patients and their spouses who participated in a five-session home counseling program reported significant improvement in such areas as symptom management, hope, uncertainty and couples communication. Prostate cancer is the most frequently diagnosed cancer in men. While treatment advances have reduced mortality rates since the early 1990s, the treatments themselves are often associated with serious permanent side effects, such as urinary incontinence or sexual dysfunction.
Varian Medical Systems Inc.: Radiating Innovation
Nov. 1, 2007 -- The National Cancer Institute estimates that in 2007 218,890 men will be diagnosed with prostate cancer in the United States. It's a disease that's gained increased attention with advancements made in screenings and treatments. A key player in many of these treatments is Palo Alto, Calif.-based medical-device manufacturer Varian Medical Systems Inc. .
|
